Short-term cultured tumor fragments to study immunotherapy combinations based on CD137 (4-1BB) agonism

References

• Perez-Gracia JL, Labiano S, Rodriguez-Ruiz ME, Sanmamed MF, Melero I. Orchestrating immune check-point blockade for cancer immunotherapy in combinations. Curr Opin Immunol. 2014;27(1):89–14. doi:10.1016/J.COI.2014.01.002.
   PubMedGoogle Scholar
• Melero I, Berman DM, Aznar MA, Korman AJ, Gracia JLP, Haanen J. Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer. 2015;15(8):457–472. doi:10.1038/nrc3973.
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Elements of cancer immunity and the cancer–immune set point. Nature. 2017;541(7637):321–330. doi:10.1038/nature21349.
   PubMed Web of Science ®Google Scholar
• Neal JT, Li X, Zhu J, Giangarra V, Grzeskowiak CL, Ju J, Liu IH, Chiou SH, Salahudeen AA, Smith AR, et al. Organoid modeling of the tumor immune microenvironment. Cell. 2018;175(7):1972–1988.e16. doi:10.1016/J.CELL.2018.11.021.
   PubMed Web of Science ®Google Scholar
• Dijkstra KK, Cattaneo CM, Weeber F, Chalabi M, van de Haar J, Fanchi LF, Slagter M, van der Velden DL, Kaing S, Kelderman S, et al. Generation of tumor-reactive T Cells by co-culture of peripheral blood lymphocytes and tumor organoids. Cell. 2018;174(6):1586–1598.e12. doi:10.1016/J.CELL.2018.07.009.
   PubMed Web of Science ®Google Scholar
• Chalabi M, Fanchi LF, Dijkstra KK, Van den Berg JG, Aalbers AG, Sikorska K, Lopez-Yurda M, Grootscholten C, Beets GL, Snaebjornsson P, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med. 2020;26(4):566–576. doi:10.1038/s41591-020-0805-8.
   PubMed Web of Science ®Google Scholar
• Voabil P, de Bruijn M, Roelofsen LM, Hendriks SH, Brokamp S, van den Braber M, Broeks A, Sanders J, Herzig P, Zippelius A, et al. An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer. Nat Med. 2021;27(7):1250–1261. doi:10.1038/s41591-021-01398-3.
   PubMed Web of Science ®Google Scholar
• Roelofsen LM, Voabil P, de Bruijn M, Herzig P, Zippelius A, Schumacher TN, Thommen DS. Protocol for ex vivo culture of patient-derived tumor fragments. Star Protoc. 2023;4(2):102282. doi:10.1016/J.XPRO.2023.102282.
   PubMedGoogle Scholar
• Pelly VS, Moeini A, Roelofsen LM, Bonavita E, Bell CR, Hutton C, Blanco-Gomez A, Banyard A, Bromley CP, Flanagan E, et al. Anti-inflammatory drugs remodel the tumor immune environment to enhance immune checkpoint blockade efficacy. Cancer Discov. 2021;11(10):2602–2619. doi:10.1158/2159-8290.CD-20-1815.
   PubMed Web of Science ®Google Scholar
• Kaptein P, Jacoberger-Foissac C, Dimitriadis P, Voabil P, De Bruijn M, Brokamp S, Reijers I, Versluis J, Nallan G, Triscott H, et al. Addition of interleukin-2 overcomes resistance to neoadjuvant CTLA4 and PD1 blockade in ex vivo patient tumors. Sci Transl Med. 2022;14(642). doi:10.1126/SCITRANSLMED.ABJ9779.
   PubMed Web of Science ®Google Scholar
• Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellström KE, Mittler RS, Chen L. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med. 1997;3(6):682–685. doi:10.1038/nm0697-682.
   PubMed Web of Science ®Google Scholar
• Melero I, Sanmamed MF, Glez-Vaz J, Luri-Rey C, Wang J, Chen L. CD137 (4-1BB)-based cancer immunotherapy on its 25th anniversary. Cancer Discov. 2023;13(3):552–569. doi:10.1158/2159-8290.CD-22-1029.
   PubMed Web of Science ®Google Scholar
• Heumann T, Judkins C, Li K, Lim SJ, Hoare J, Parkinson R, Cao H, Zhang T, Gai J, Celiker B, et al. A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma. Nat Commun. 2023;14(1). doi:10.1038/S41467-023-39196-9.
   PubMed Web of Science ®Google Scholar
• Tolcher AW, Sznol M, Hu-Lieskovan S, Papadopoulos KP, Patnaik A, Rasco DW, Di Gravio D, Huang B, Gambhire D, Chen Y, et al. Phase Ib Study of utomilumab (PF-05082566), a 4-1BB/CD137 agonist, in combination with pembrolizumab (MK-3475) in patients with advanced solid tumors. Clin Cancer Res. 2017;23(18):5349–5357. doi:10.1158/1078-0432.CCR-17-1243.
   PubMed Web of Science ®Google Scholar
• Muik A, Garralda E, Altintas I, Gieseke F, Geva R, Ben-Ami E, Maurice-Dror C, Calvo E, Lorusso PM, Alonso G, et al. Preclinical characterization and phase I trial results of a bispecific antibody targeting PD-L1 and 4-1BB (GEN1046) in patients with advanced refractory solid tumors. Cancer Discov. 2022;12(5):1248–1265. doi:10.1158/2159-8290.CD-21-1345.
   PubMed Web of Science ®Google Scholar
• Sanmamed MF, Berraondo P, Rodriguez-Ruiz ME, Melero I. Charting roadmaps towards novel and safe synergistic immunotherapy combinations. Nat Cancer. 2022;3(6):665–680. doi:10.1038/s43018-022-00401-1.
   PubMedGoogle Scholar
• Morales-Kastresana A, Sanmamed MF, Rodriguez I, Palazon A, Martinez-Forero I, Labiano S, Hervas-Stubbs S, Sangro B, Ochoa C, Rouzaut A, et al. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model. Clin Cancer Res. 2013;19(22):6151–6162. doi:10.1158/1078-0432.CCR-13-1189.
   PubMed Web of Science ®Google Scholar
• Ochoa MC, Sanchez-Gregorio S, de Andrea CE, Garasa S, Alvarez M, Olivera I, Glez-Vaz J, Luri-Rey C, Etxeberria I, Cirella A, et al. Synergistic effects of combined immunotherapy strategies in a model of multifocal hepatocellular carcinoma. Cell Rep Med. 2023;4(4):101009. doi:10.1016/j.xcrm.2023.101009.
   PubMedGoogle Scholar
• Azpilikueta A, Agorreta J, Labiano S, Pérez-Gracia JL, Sánchez-Paulete AR, Aznar MA, Ajona D, Gil-Bazo I, Larrayoz M, Teijeira A, et al. Successful immunotherapy against a transplantable mouse squamous lung carcinoma with Anti–PD-1 and Anti-CD137 monoclonal antibodies. J Thorac Oncol. 2016;11(4):524–536. doi:10.1016/J.JTHO.2016.01.013.
   PubMed Web of Science ®Google Scholar
• Labiano S, Palazón A, Bolaños E, Azpilikueta A, Sánchez-Paulete AR, Morales-Kastresana A, Quetglas JI, Perez-Gracia JL, Gúrpide A, Rodriguez-Ruiz M, et al. Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism. Oncoimmunology. 2015;5(1):e1062967. doi:10.1080/2162402X.2015.1062967.
   PubMed Web of Science ®Google Scholar
• Palazón A, Martínez-Forero I, Teijeira A, Morales-Kastresana A, Alfaro C, Sanmamed MF, Perez-Gracia JL, Peñuelas I, Hervás-Stubbs S, Rouzaut A, et al. The HIF-1α hypoxia response in tumor-infi ltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy. Cancer Discov. 2012;2(7):608–623. doi:10.1158/2159-8290.CD-11-0314.
   PubMed Web of Science ®Google Scholar
• Glez-Vaz J, Azpilikueta A, Olivera I, Cirella A, Teijeira A, Ochoa MC, Alvarez M, Eguren-Santamaria I, Luri-Rey C, Rodriguez-Ruiz ME, et al. Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies. J Immunother Cancer. 2022;10(3):e003532. doi:10.1136/JITC-2021-003532.
   PubMed Web of Science ®Google Scholar
• Martinez-Forero I, Azpilikueta A, Bolaños-Mateo E, Nistal-Villan E, Palazon A, Teijeira A, Perez-Chacon G, Morales-Kastresana A, Murillo O, Jure-Kunkel M, et al. T cell costimulation with anti-CD137 monoclonal antibodies is mediated by K63–polyubiquitin-dependent signals from endosomes. The J Immunol. 2013;190(12):6694–6706. doi:10.4049/JIMMUNOL.1203010.
   PubMed Web of Science ®Google Scholar
• LaMarche NM, Hegde S, Park MD, Maier BB, Troncoso L, Le Berichel J, Hamon P, Belabed M, Mattiuz R, Hennequin C, et al. An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis. Nature. 2024;625(7993):166–174. doi:10.1038/S41586-023-06797-9.
   PubMedGoogle Scholar
• Tauriello DVF, Palomo-Ponce S, Stork D, Berenguer-Llergo A, Badia-Ramentol J, Iglesias M, Sevillano M, Ibiza S, Cañellas A, Hernando-Momblona X, et al. TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis. Nature. 2018;554(7693):538–543. doi:10.1038/NATURE25492.
   PubMed Web of Science ®Google Scholar
• Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel EE, Koeppen H, Astarita JL, Cubas R, et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554(7693):544–548. doi:10.1038/NATURE25501.
   PubMed Web of Science ®Google Scholar
• Massagué J, Sheppard D. TGF-β signaling in health and disease. Cell. 2023;186(19):4007–4037. doi:10.1016/J.CELL.2023.07.036.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Ruiz ME, Rodríguez I, Mayorga L, Labiano T, Barbes B, Etxeberria I, Ponz-Sarvise M, Azpilikueta A, Bolaños E, Sanmamed MF, et al. TGFβ blockade enhances radiotherapy abscopal efficacy effects in combination with anti-PD1 and Anti-CD137 immunostimulatory monoclonal antibodies. Mol Cancer Ther. 2019;18(3):621–631. doi:10.1158/1535-7163.MCT-18-0558.
   PubMed Web of Science ®Google Scholar
• Segal NH, Logan TF, Hodi FS, McDermott D, Melero I, Hamid O, Schmidt H, Robert C, Chiarion-Sileni V, Ascierto PA, et al. Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody. Clin Cancer Res. 2017;23(8):1929–1936. doi:10.1158/1078-0432.CCR-16-1272.
   PubMed Web of Science ®Google Scholar
• Melero I, Tanos T, Bustamante M, Sanmamed MF, Calvo E, Moreno I, Moreno V, Hernandez T, Garcia MM, Rodriguez-Vida A, et al. A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors. Sci Transl Med. 2023;15(695). doi:10.1126/SCITRANSLMED.ABP9229.
   PubMed Web of Science ®Google Scholar
• Thibaut R, Bost P, Milo I, Cazaux M, Lemaître F, Garcia Z, Amit I, Breart B, Cornuot C, Schwikowski B, et al. Bystander IFN-γ activity promotes widespread and sustained cytokine signaling altering the tumor microenvironment. Nat Cancer. 2020;1(3):302–314. doi:10.1038/S43018-020-0038-2.
   PubMedGoogle Scholar
• Larson RC, Kann MC, Bailey SR, Haradhvala NJ, Llopis PM, Bouffard AA, Scarfó I, Leick MB, Grauwet K, Berger TR, et al. CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours. Nature. 2022;604(7906):563–570. doi:10.1038/S41586-022-04585-5.
   PubMed Web of Science ®Google Scholar
• de Witte CJ, Espejo Valle-Inclan J, Hami N, Lõhmussaar K, Kopper O, Vreuls CPH, Jonges GN, van Diest P, Nguyen L, Clevers H, et al. Patient-derived ovarian cancer organoids mimic clinical response and exhibit heterogeneous inter- and intrapatient drug responses. Cell Rep. 2020;31(11):107762. doi:10.1016/J.CELREP.2020.107762.
   PubMed Web of Science ®Google Scholar
• Jiang S, Zhao H, Zhang W, Wang J, Liu Y, Cao Y, Zheng H, Hu Z, Wang S, Zhu Y, et al. An automated organoid platform with inter-organoid homogeneity and inter-patient heterogeneity. Cell Rep Med. 2020;1(9):100161. doi:10.1016/J.XCRM.2020.100161.
   PubMedGoogle Scholar
• Sánchez-Paulete AR, Teijeira A, Cueto FJ, Garasa S, Pérez-Gracia JL, Sánchez-Arráez A, Sancho D, Melero I. Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy. Ann Oncol. 2017;28(suppl_12):xii74. doi:10.1093/ANNONC/MDX727.
   PubMedGoogle Scholar
• Kamer I, Bab-Dinitz E, Zadok O, Ofek E, Gottfried T, Daniel-Meshulam I, Hout-Siloni G, Ben Nun A, Barshack I, Onn A, et al. Immunotherapy response modeling by ex-vivo organ culture for lung cancer. Cancer Immunol, Immunother. 2021;70(8):2223–2234. doi:10.1007/s00262-020-02828-w.
   PubMed Web of Science ®Google Scholar
• Sivakumar R, Chan M, Shin JS, Nishida-Aoki N, Kenerson HL, Elemento O, Beltran H, Yeung R, Gujral TS. Organotypic tumor slice cultures provide a versatile platform for immuno-oncology and drug discovery. Oncoimmunology. 2019;8(12):e1670019. doi:10.1080/2162402X.2019.1670019.
   PubMed Web of Science ®Google Scholar
• Deng J, Wang ES, Jenkins RW, Li S, Dries R, Yates K, Chhabra S, Huang W, Liu H, Aref AR, et al. CDK4/6 inhibition augments antitumor immunity by enhancing T-cell activation. Cancer Discov. 2018;8(2):216–233. doi:10.1158/2159-8290.CD-17-0915.
   PubMed Web of Science ®Google Scholar
• Jenkins RW, Aref AR, Lizotte PH, Ivanova E, Stinson S, Zhou CW, Bowden M, Deng J, Liu H, Miao D, et al. Ex vivo profiling of PD-1 blockade using organotypic tumor spheroids. Cancer Discov. 2018;8(2):196–215. doi:10.1158/2159-8290.CD-17-0833.
   PubMed Web of Science ®Google Scholar
• Brandes AA, Carpentier AF, Kesari S, Sepulveda-Sanchez JM, Wheeler HR, Chinot O, Cher L, Steinbach JP, Capper D, Specenier P, et al. A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. Neuro Oncol. 2016;18(8):1146–1156. doi:10.1093/NEUONC/NOW009.
   PubMed Web of Science ®Google Scholar
• Melisi D, Oh DY, Hollebecque A, Calvo E, Varghese A, Borazanci E, Macarulla T, Merz V, Zecchetto C, Zhao Y, et al. Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer. J Immunother Cancer. 2021;9(3):e002068. doi:10.1136/JITC-2020-002068.
   PubMed Web of Science ®Google Scholar
• Nadal E, Saleh M, Aix SP, Ochoa-de-Olza M, Patel SP, Antonia S, Zhao Y, Gueorguieva I, Man M, Estrem ST, et al. A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer. BMC Cancer. 2023;23(1):1–13. doi:10.1186/s12885-023-11153-1.
   PubMed Web of Science ®Google Scholar
• Strauss J, Heery CR, Schlom J, Madan RA, Cao L, Kang Z, Lamping E, Marte JL, Donahue RN, Grenga I, et al. Phase I Trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGFβ, in advanced solid tumors. Clin Cancer Res. 2018;24(6):1287–1295. doi:10.1158/1078-0432.CCR-17-2653.
   PubMed Web of Science ®Google Scholar
• Cho BC, Lee JS, Wu YL, Cicin I, Dols MC, Ahn MJ, Cuppens K, Veillon R, Nadal E, Dias JM, et al. Bintrafusp Alfa versus pembrolizumab in patients with treatment-naive, programmed death-ligand 1-high advanced NSCLC: a randomized, open-label, phase 3 trial. J Thorac Oncol. 2023;18(12):1731–1742. doi:10.1016/J.JTHO.2023.08.018.
   PubMed Web of Science ®Google Scholar
• Vokes EE, Mornex F, Sezer A, Cheng Y, Fang J, Baz DV, Cil T, Adjei AA, Ahn MJ, Barlesi F, et al. Bintrafusp Alfa with CCRT followed by Bintrafusp Alfa versus Placebo with CCRT followed by Durvalumab in Patients with Unresectable Stage III NSCLC: a phase 2 randomized study. J Thorac Oncol. 2024;19(2):285–296. doi:10.1016/J.JTHO.2023.09.1452.
   PubMed Web of Science ®Google Scholar
• Leem G, Park J, Jeon M, Kim ES, Kim SW, Lee YJ, Choi SJ, Choi B, Park S, Ju YS, et al. 4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39+ CD8 T cells from primary and metastatic sites of epithelial ovarian cancers. J Immunother Cancer. 2020;8(2):e001650. doi:10.1136/JITC-2020-001650.
   PubMed Web of Science ®Google Scholar
• Shen Y, Li XL, Li YX, Shan ZG, Zhao YL, Cheng P, Zhao Z, Zhang JY, Chen W, Zhuang Y, et al. Distribution, phenotype, functional and clinical relevance of CD8+CD103+ tissue-resident memory T cells in human gastric cancer. Cancer Immunol, Immunother. 2022;71(7):1645–1654. doi:10.1007/s00262-021-03105-0.
   PubMed Web of Science ®Google Scholar
• Amaria R, Knisely A, Vining D, Kopetz S, Overman MJ, Javle M, Antonoff MB, Tzeng CWD, Wolff RA, Pant S, et al. Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. J Immunother Cancer. 2024;12(2):e006822. doi:10.1136/JITC-2023-006822.
   PubMedGoogle Scholar
• Mellman I, Chen DS, Powles T, Turley SJ. The cancer-immunity cycle: indication, genotype, and immunotype. Immunity. 2023;56(10):2188–2205. doi:10.1016/J.IMMUNI.2023.09.011.
   PubMed Web of Science ®Google Scholar